Background

Pure autonomic failure (PAF) is a synucleinopathy characterized by orthostatic hypotension, autonomic, orthostatic, and autonomic dysfunction, and bladder involvement. Most patients survive for decades without clinical central nervous system involvement. However, a subset of patients originally diagnosed as PAF ultimately develops extrapyramidal or cerebellar motor symptoms and evolves to multiple system atrophy (MSA). Parkinson’s disease (PD) or diffuse Lewy body disease (LBD). The current literature provides little information on findings of MSA converters (possible PAF). In order to assess for the presence or absence of progression we reviewed the Mayo Autonomic database.

Objectives

To identify predictors of conversion of PAF to more sinister synucleinopathies with motor involvement.

Methods

We reviewed patients seen at Mayo Clinic by an autonomic specialist between 1/1/2000 and 7/1/2010, and underwent standardised autonomic reflex testing revealing orthostatic hypotension (OH). OH was defined as a drop in BP of >30mmHg systolic or >15mmHg diastolic.

1427 patients with 4736 unique visits were identified and each was evaluated for a diagnosis of PAF (possible PAF). Patients with diagnoses of diabetes mellitus, amyloidosis, autoimmune ganglionopathies (positive for anti-ganglioside antibodies), and neurogenic orthostatic hypotension were excluded. 319 patients fulfilled these criteria.

In order to assess for the presence or absence of progression we identified patients with 3 years or more of in-person follow-up (stable PAF) and/or documented progression to another synucleinopathy (converters). To identify predictors of conversion we assessed relative risk and odds of conversion based on clinical, autonomic, and laboratory variables.

Results

Among 319 patients fulfilling criteria for possible PAF, we identified 41 patients with stable PAF and 38 (12%) converters. Of those who evolved, 22 developed MSA, 11 developed PD or LBD, and 5 remained indeterminate.

The median time to conversion to MSA was 2.4 years, with an interquartile range of 1.9-3.3 years. This suggests that the majority of PAF to MSA conversion occurs during the first 3 to 4 years after the diagnosis of PAF.

Five variables were identified to be significant predictors of conversion to MSA (Table 1): 1) Vagal CASS score 2) Preganglionic pattern of sweat loss 3) Severe bladder dysfunction (urinary retention, catheterization, incontinence) 4) Supine noradrenaline >100 pg/ml 5) Subtle motor signs at first presentation

By adding one point for the presence of each of these five variables (Fig. 1), individual predictors were converted into a MSA conversion score, this allowed for prediction of conversion with high accuracy. A score of 0 to 1 affirms a diagnosis of PAF and is associated with a low risk of conversion to MSA. A score of 2 is intermediate and associated with a moderately increased risk of conversion. A score greater than 2 strongly predicts conversion to MSA with a sensitivity of 88% and specificity of 98%, while a score greater than 3 shows 100% specificity for conversion.

Individuals who converted to LBD or PD had less severe autonomic involvement than those stable PAF or MSA conversion group.

Conclusion

Over 10% of patients originally diagnosed as PAF eventually evolve to develop clinical CNS involvement, most commonly MSA.

Utilizing clinical, autonomic, and laboratory data, we have identified 5 variables associated with an increased risk of conversion.

In combination, these factors allow for prediction of conversion from PAF to MSA with high diagnostic accuracy.


des

Supported by NIHS154423, US4NS056736, K23NS075141, LR924150, Mayo Funds, and the Kathy Shih Foundation.